HAE Stock Analysis: Buy, Sell, or Hold?
HAE - Haemonetics Corporation
$86.79
1.25 (1.46%)
▲
5d:
+8.61%
30d:
+15.61%
90d:
+46.46%
HOLD
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 06, 2026
1d
Get Alerted When HAE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: HAE trades at premium valuation expecting 8.1% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: HAE trades at premium valuation expecting 8.1% growth. Hold existing positions but don't chase. Wait for better entry.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$89.88
Based on 5.5% avg growth
INTRINSIC VALUE TODAY
$55.81
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 13.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HAE is currently trading at $86.79, which is considered extended relative to its 30-day fair value range of $74.48 to $81.79. From a valuation perspective, the stock is trading at a premium (Forward PE: 16.4) compared to its historical average (13.0). At these levels, the market is pricing in 8.1% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, HAE is in a strong uptrend. The price is approaching resistance at $88.58. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: HAE has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, HAE is in a strong uptrend. The price is approaching resistance at $88.58. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: HAE has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$74.48 -
$81.79
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
51.4%
All Signals
- BEARISH: Price extended above range (+6.1% above its trading range)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($87.90)
- NEUTRAL: Trading at premium valuation - market expects 8.1% growth which is achievable
Trading Range Analysis
30-Day Trading Range
$74.48 -
$81.79
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$74.95
Resistance Level
$88.59
Current Trend
Strong Uptrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
16.40
Wall Street Target
$87.90
(+1.3%)
Revenue Growth (YoY)
4.8%
Earnings Growth (YoY)
28.4%
Profit Margin
7.3%
Valuation Premium vs History
+8.1% premium
PE vs Historical
16.4 vs 13.0
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+8.1%
(market-implied from PE analysis)
1-Year Target
$93.82
(+8%)
2-Year Target
$101.42
(+17%)
3-Year Target
$109.63
(+26%)
3-Yr Target (if PE normalizes)
(PE: 16→13)
PE COMPRESSION
$86.89
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.7, Growth: 7.0%)
$134.53
(+55%)
Base:
(SPY PE: 16.4, Growth: 7.0%)
$106.45
(+23%)
Bear:
(PE: 13.0, Growth: 7.0%)
$84.37
(-3%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (42x PE), but valuation improves significantly next year (16x PE) as earnings recover.
Trailing PE: 41.73 | Current EPS (TTM): $2.05
Bull Case
$188.19
(+117%)
Analyst growth 100.0%, PE expands to 45.9
Base Case
$171.08
(+97%)
Market implied 100.0%, PE stable at 41.7
Bear Case
$58.17
(-33%)
Severe decline -20.0%, PE contracts to 35.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 03, 2026 8:20 PM ET
Data refreshes hourly during market hours. Next update: 9:20 PM
Data refreshes hourly during market hours. Next update: 9:20 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HAE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$93 | 49 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$384 | 51 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$118 | 52 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$101 | 52 HOLD |
|
ZBH
Zimmer Biomet Holdings I… |
HOLD
29 analysts |
$99 | 60 HOLD |
